49th week of 2014 patent applcation highlights part 57 |
Patent application number | Title | Published |
20140357629 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds and methods for treating diseases mediated by a P2X | 2014-12-04 |
20140357630 | Phenylacetic Acid Compound - A compound represented by formula (I), | 2014-12-04 |
20140357631 | SUCCINIMIDE COMPOUND - A compound represented by formula (1): | 2014-12-04 |
20140357632 | BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS - Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. | 2014-12-04 |
20140357633 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS - The present invention relates to compounds of formula I: in which R | 2014-12-04 |
20140357634 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 2014-12-04 |
20140357635 | ACTIVE COMPOUND COMBINATIONS - The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed. | 2014-12-04 |
20140357636 | Treatment of Skeletal-Related Disorders - The invention relates to the prevention and/or treatment of skeletal related disorders using heteroaryl compounds. | 2014-12-04 |
20140357637 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF - The present application relates to novel substituted fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders. | 2014-12-04 |
20140357638 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE - The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same. | 2014-12-04 |
20140357639 | Imidazole derivatives as PDE10 enzyme inhibitors - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2014-12-04 |
20140357640 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them. | 2014-12-04 |
20140357641 | IP receptor agonist heterocyclic compounds - The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (I): | 2014-12-04 |
20140357642 | IP receptor agonist heterocyclic compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 2014-12-04 |
20140357643 | Derivatives of Betulin - The present invention relates to compounds characterized by having a structure according to the following Formula I: | 2014-12-04 |
20140357644 | HYDROXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula I: | 2014-12-04 |
20140357645 | Advanced Formulations and Therapies for Treating Hard-to-Heal Wounds - A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof. | 2014-12-04 |
20140357646 | POLYMORPHS - The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. | 2014-12-04 |
20140357647 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel 7-substituted fangchinoline derivatives of formula (I) and a pharmaceutically acceptable adduct, complex and salt thereof, to a process for the preparation of these compounds, pharmaceutical compositions containing such compounds and their use in preparing antineoplastic medicaments. | 2014-12-04 |
20140357648 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER'S DISEASE - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s), can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder. | 2014-12-04 |
20140357649 | Phenyl(oxy/thio)alkanol Derivatives - The present invention relates to novel phenyl(oxy/thio)alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. | 2014-12-04 |
20140357650 | NOVEL FAP INHIBITORS - The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders. | 2014-12-04 |
20140357651 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition. | 2014-12-04 |
20140357652 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 2014-12-04 |
20140357653 | CHEMICAL COMPOUNDS - The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO | 2014-12-04 |
20140357654 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP - Embodiments of the invention relate to the treatment of schizophrenia in mammals. Embodiments of the invention include methods for treating schizophrenia and/or symptoms of schizophrenia and/or a positive symptom of schizophrenia in a psychotic disease as well as methods for preparing medicaments used in the treatment of mammalian schizophrenia. In one embodiment, methods of the invention comprise the inhibition of alpha4 integrin by a genus of compounds for the treatment of mammalian schizophrenia or a positive symptom of schizophrenia in a psychotic disease. | 2014-12-04 |
20140357655 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS - Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. | 2014-12-04 |
20140357656 | Bivalent Ligands for the Treatment of Neurological Disorders - Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS. | 2014-12-04 |
20140357657 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2014-12-04 |
20140357659 | METHOD FOR PREDICTING AND EVALUATING RESPONSIVENESS TO CANCER TREATMENT WITH DNA-DAMAGING CHEMOTHERAPEUTIC AGENTS - Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment. | 2014-12-04 |
20140357660 | GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY - Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mTORi/HDACi combination therapy and/or for determining the prognosis of a neoplasm in a subject are described. Some embodiments include determining whether a neoplasm is sensitive to mTORi/HDACi combination therapy by predicting whether mTORi/HDACi combination therapy will successfully treat the neoplasm, for example increasing survival of the subject with the neoplasm. In some embodiments, determining the prognosis includes predicting the outcome (such as chance of survival) of the subject with a neoplasm. Also disclosed are reagents, for example arrays, for use with the disclosed methods, as well as computer implementation of the disclosed methods. | 2014-12-04 |
20140357661 | CHEMICAL COMPOUNDS - The invention concerns compounds of Formula (I) | 2014-12-04 |
20140357662 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS - The present invention provides compounds of formula (I): wherein A, R | 2014-12-04 |
20140357663 | 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,- 3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREAAND RELATED COMPOUNDS AND THEIR USE IN THERAPY - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer. | 2014-12-04 |
20140357664 | 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS - The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia. | 2014-12-04 |
20140357665 | Opsin-Binding Ligands, Compositions and Methods of Use - Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed. | 2014-12-04 |
20140357666 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS - The present invention relates to compounds of formula I: in which R | 2014-12-04 |
20140357667 | TREATMENT OF CEREBRAL PALSY IMPAIRED SPEECH IN CHILDREN - Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment. | 2014-12-04 |
20140357668 | TREATMENT OF CEREBRAL PALSY IMPAIRED SPEECH IN CHILDREN - Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment. | 2014-12-04 |
20140357669 | TAZAROTENE DERIVATIVES - The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives. | 2014-12-04 |
20140357670 | DIHYDROPYRIDINONE MGAT2 INHIBITORS - The present invention provides compounds of Formula (I): | 2014-12-04 |
20140357671 | SPOT-ON PESTICIDE COMPOSITION - A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises fipronil, etofenprox, and an insect growth regulator as the active components, in doses and proportions which are effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area. | 2014-12-04 |
20140357672 | TAZAROTENE DERIVATIVES - The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives. | 2014-12-04 |
20140357673 | Deubiquitinase Inhibitors and Methods for Use of the Same - Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds. | 2014-12-04 |
20140357674 | NICOTINIC RECEPTOR COMPOUNDS - Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2′-fluoro-3′-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors. | 2014-12-04 |
20140357675 | Substituted Phenylazole Derivatives - Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 2014-12-04 |
20140357676 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING - A pharmaceutical composition is provided which includes sorafenib and GW5074. This combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either an in vitro or pre-clinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. A novel pharmaceutical composition is provided which includes sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening. | 2014-12-04 |
20140357677 | N-METHYL-4-BENZYLCARBAMIDOPYRIDINIUM CHLORIDE AND A PROCESS FOR ITS PREPARATION - The present application relates to a new salt of N-methyl-4-benzylcarbami-dopyridine, a process for its preparation, a pharmaceutical composition comprising this compound and its use for the treatment or prevention of viral diseases. | 2014-12-04 |
20140357678 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - A pharmaceutically acceptable salt, prodrug or derivative compound of the formula I, wherein R | 2014-12-04 |
20140357679 | ACTIVE COMPOUND COMBINATIONS - The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed. | 2014-12-04 |
20140357680 | COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES - The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance. | 2014-12-04 |
20140357681 | Composition for Hot-Melt Extrusion and Method for Producing Hot-Melt Extrusion Product Using Same - Provided are a composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product including a step of hot-melt extruding a composition for hot-melt extrusion including a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted. | 2014-12-04 |
20140357682 | ANDROGEN RECEPTOR LIGANDS - Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (AR) is a member of the Nuclear Receptor (NR) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (DHT). Synthetic androgens and anti-androgens have therapeutic value in the treatment of various androgen dependent conditions, from regulation of male fertility to prostate cancer. Current treatment of prostate cancer (PCa) typically involves administration of ‘classical’ antiandrogens, competitive inhibitors of natural AR ligands, DHT and tes, for the ligand binding pocket (LBP) in the C-terminal ligand binding domain (LBD) of the AR. However, prolonged LBP-targeting can often lead to androgen resistance and alternative therapies and therapeutic strategies are urgently required. Disclosed herein are a class of non-steroidal, small molecule AR antagonists which inhibit the transcriptional activity of the AR by non LBP-mediated modulation. The novel class reported demonstrates full (‘true’) antagonism in AR with low micromolar potency, high selectivity over both the Estrogen Receptors alpha and beta (ERα and ERβ) and the Glucocorticoid Receptor (GR) and only micromolar partial antagonism in the Progesterone Receptor (PR). Data provide compelling evidence for such non-LBP intervention as an alternative approach to classical PCa therapy. (Formula I). | 2014-12-04 |
20140357683 | METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS - Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient. | 2014-12-04 |
20140357684 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME - The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient. | 2014-12-04 |
20140357685 | Sodium Channel Inhibitors - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel. | 2014-12-04 |
20140357686 | METHOD OF TREATING DISEASE BY AURICULAR ANESTHESIA OF CRANIAL NERVES - Methods for treating a variety of diseases that comprises performing auricular anesthesia of the vagus, facial, trigeminal, or glossopharyngeal nerves, or combinations thereof. A pharmaceutical composition is administered to an ear canal of a subject in need of such treatment, the composition including an analgesic and an anesthetic. Compositions useful in the taught methods are also provided. | 2014-12-04 |
20140357687 | Pyrazol-3-ones That Activate Pro-apoptotic BAX - This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells). | 2014-12-04 |
20140357688 | METHOD FOR INHIBITING EZH2 EXPRESSION IN BREAST CANCER CELLS - The present invention is directed to a method for inhibiting the overexpression of EZH2 in breast cancer cells. The method comprises administering to breast cancer cells an effective amount of YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole), YC-1-succinate (succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester), or a pharmaceutically acceptable salt thereof. The present invention is also directed to treating breast cancer comprising administering to a subject an effective amount of YC-1-succinate. | 2014-12-04 |
20140357689 | METHOD FOR TREATING ABNORMAL POLYGLUTAMINE-MEDIATED DISEASE - A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy. | 2014-12-04 |
20140357690 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROC- YCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF - The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis). | 2014-12-04 |
20140357691 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid - Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. | 2014-12-04 |
20140357692 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 2014-12-04 |
20140357693 | METABOLIC GENE MESENCHYMAL SIGNATURES AND USES THEREOF - Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection. | 2014-12-04 |
20140357694 | RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example. | 2014-12-04 |
20140357695 | RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS - RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease. | 2014-12-04 |
20140357696 | RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 2014-12-04 |
20140357697 | Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 - The present invention provides materials and methods related to modulation of mismatch repair and genomic stability by miR-155. | 2014-12-04 |
20140357698 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE - The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides. | 2014-12-04 |
20140357699 | MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING ADVERSE ENERGY METABOLISM SWITCHES IN HEART DISEASE - The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease. | 2014-12-04 |
20140357700 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 2014-12-04 |
20140357701 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions. | 2014-12-04 |
20140357702 | MicroRNA Expression Profile Associated With Pancreatic Cancer - Methods are provided for diagnosing whether a subject has, or is at risk of developing, pancreatic cancer. The methods include measuring the level of at least one miR gene product in a biological sample derived from the subject's pancreas. An alteration in the level of the miR gene product in the biological sample as compared to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer. | 2014-12-04 |
20140357703 | Stem Cell Derived Factors for Treating Pathologic Conditions - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions. | 2014-12-04 |
20140357704 | RTEF-1 VARIANTS AND USES THEREOF - Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention. | 2014-12-04 |
20140357705 | SUBSTITUTED CYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein are compounds having a formula: | 2014-12-04 |
20140357706 | Stearate Compounds - Preparation and methods of treating and preventing visceral adiposity and cancer are provided involving the administration of stearate to a subject. It has been unexpectedly discovered that the fatty acid stearate, when introduced in the diet, reduces the amount of visceral fat in the body without decreasing overall body weight or causing measurable negative side effects. It has also been unexpectedly discovered that dietary stearate prevents cancer in healthy subjects and reduces both tumor size and metastasis in subjects already afflicted with cancer. | 2014-12-04 |
20140357707 | INSECT PEST-TARGETING GEL COMPOSITION AND SUSTAINED RELEASE PREPARATION COMPRISING THAT - Provided are an insect pest-targeting gel composition causing neither leakage nor reaction of a volatile substance and capable of releasing the volatile substance at a constant rate; and a sustained release preparation including the insect pest-targeting gel composition. More specifically, provided is an insect pest-targeting gel composition including one or more volatile substances and an oil gelling agent, wherein the volatile substance is included in an amount of from 70.0 to 99.0% by weight by the insect pest-targeting gel composition. | 2014-12-04 |
20140357708 | ORAL DOSAGE FORM OF TETRAHYDROCANNABINOL AND A METHOD OF AVOIDING AND/OR SUPPRESSING HEPATIC FIRST PASS METABOLISM VIA TARGETED CHYLOMICRON/LIPOPROTEIN DELIVERY - An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) about 15 to 85 wt % of one or more triglycerides formed from long chain fatty having from C | 2014-12-04 |
20140357709 | PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS - (Modified) | 2014-12-04 |
20140357710 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 2014-12-04 |
20140357711 | Amooranin Compounds and Analogs Thereof and Related Methods of Use - Methods for synthesizing amooranin (25-hydroxy-3-oxoolean-12-en-28-oic acid (AMR) and/or amooranin analogs, including amooranin methyl ester (AMR-Me), by using oleanolic acid in an oxidation process, and therapeutic uses thereof are described. | 2014-12-04 |
20140357712 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 2014-12-04 |
20140357713 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 2014-12-04 |
20140357714 | COMPOSITIONS COMPRISING METATHESIZED UNSATURATED POLYOL ESTERS - Disclosed are petrolatum-like compositions that include metathesized unsaturated polyol esters. Also disclosed are emulsions that include metathesized unsaturated polyol esters. The petrolatum-like compositions may be used as substitutes for petroleum-based petrolatum. The emulsions may be water-in-oil or oil-in-water emulsions and may be suitable for a variety of end uses. | 2014-12-04 |
20140357715 | ANORECTIC AGENT - The present invention provides an anorectic agent comprising palmitoleic acid as an active ingredient. | 2014-12-04 |
20140357716 | COMPOSITE MATERIAL FOR TISSUE REPAIR - The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site. | 2014-12-04 |
20140357717 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2014-12-04 |
20140357718 | COMPOSITIONS FOR USE IN CONTROLLING INTESTINAL MICROFLORA - The present invention relates to compositions containing organic acids and emulsifiers and their use in controlling intestinal microflora in production animals. In particular, the present invention relates to the use of such compositions for reducing foodborne pathogens. | 2014-12-04 |
20140357719 | METHODS OF USING OMEGA-3 FATTY ACIDS - A method for influencing behavior in young, adult or aged pet animals which comprises systemically administering a behavior influencing quantity of an omega-3 fatty acid or mixture of omega-3 fatty acids. | 2014-12-04 |
20140357720 | NOVEL PHYTOSPHINGOSINE DERIVATIVES, AND A COSMETIC COMPOSITION COMPRISING THE SAME FOR PREVENTING AND AMELIORATING INFLAMMATORY SKIN DISEASES AND HYPERKERATOSIS DISEASES - A phytosphingosine derivatives of chemical formula IA or IB, and a cosmetic composition including the phytosphingosine derivative. The phytosphingosine derivatives are involved with transcription factors related to inflammation and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like. | 2014-12-04 |
20140357721 | REDISPERSIBLE POWDER-DISPERSED COSMETIC - Provided is a redispersible powder-dispersed cosmetic which has a clear supernatant when unused, can exhibit good powder redispersibility when shaken upon use, has a good sensation, e.g., smoothness and non-stickiness, upon application to the skin, and has an excellent effect of dissolving/removing keratotic plugs. The cosmetic is characterized by comprising (A) succinic acid and/or a salt thereof, (B) bentonite and (C) a hydrophilic surfactant. Particularly preferably, the cosmetic additionally comprises a cellulose powder. It is preferred that the component (A), i.e., succinic acid and/or the salt thereof, is contained in an amount of 0.01 to 10.0 mass % relative to the total amount of the cosmetic. | 2014-12-04 |
20140357722 | Use of Malononitrilamides in Neuropathic Pain - Provided herein are compounds and pharmaceutical compositions for use in the treatment of neuropathic pain and the neuropathic pain syndromes. | 2014-12-04 |
20140357723 | Tricholine Nasal Formulation and Method of Use - A commercially-suitable tricholine nasal formulation for administration to a human as a nasal spray is disclosed. The tricholine nasal formulation includes an aqueous solution of tricholine citrate, a volatile oil and a buffer system. The disclosed tricholine nasal formulation possesses an acceptable odor and a reasonable shelf-life. The tricholine nasal formulation may be used to treat the symptoms associated with stress, anxiety, depression, malaise, or “burn out” syndrome. Optionally, a moisturizer is included in the composition to alleviate any dryness resulting from administration of the formulation to a user. A preservative may be included in the composition to produce a longer shelf-life. | 2014-12-04 |
20140357724 | BETA 2 ADRENOCEPTOR ANTAGONISTS FOR TREATING ORTHOSTATIC HYPOTENSION - Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol. | 2014-12-04 |
20140357725 | TERPENE ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS - The present application provides terpene analogues of Formula 1 and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain specifically. | 2014-12-04 |
20140357726 | USE OF PEGYLATED ALCOHOLS FOR THE TREATMENT OF ACTINIC KERATOSIS - Use of pegylated alcohols for the treatment of actinic keratosis. | 2014-12-04 |
20140357727 | FATTY ALCOHOL FORMING ACYL REDUCTASE (FAR) VARIANTS AND METHODS OF USE - The present disclosure provides methods useful for producing fatty alcohol compositions from recombinant host cells. The disclosure further provides fatty acyl-CoA reductase (FAR) variant enzymes, polynucleotides encoding the FAR variant enzymes, and vectors and host cells comprising polynucleotides encoding the FAR variant enzymes. | 2014-12-04 |
20140357728 | PESTICIDES BASED ON VICINAL DIOLS - Pesticides based on hydroxy-substituted hydrocarbyl compounds, particularly vicinal diols, are available to control arthropod ectoparasites such as | 2014-12-04 |
20140357729 | TOPICAL COMPOSITION CONTAINING SILICONE BASE - It is an object to provide a topical composition that is excellent in texture and feeling upon use. The present invention is a topical composition without water, satisfying the following: (A) the composition includes a silicone base in a proportion of 80% by weight or more; (B) the silicone base includes (b1) a silicone elastomer, (b2) a cyclic volatile methylsiloxane having 3 to 6 silicon atoms, and (b3) a linear dimethylpolysiloxane and/or linear methylphenylpolysiloxane; (C) the composition includes therein an active ingredient present in a dispersed or dissolved type; and (D) the composition does not contain any non-silicone thickener. | 2014-12-04 |